Literature DB >> 7853490

Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection.

H Petry1, U Dittmer, C Stahl-Hennig, C Coulibaly, B Makoschey, D Fuchs, H Wachter, T Tolle, C Morys-Wortmann, F J Kaup.   

Abstract

By superinfection of human immunodeficiency virus type 2 (HIV-2) strain HIV-2ben-infected macaques with simian immunodeficiency virus (SIV) strain SIVmac, we investigated the mutual influences of an apathogenic and a pathogenic virus in vivo. Four rhesus and two cynomolgus monkeys were infected with HIV-2ben in 1988 and 1989, respectively. Virus could be reisolated from five of six animals 6 weeks after infection. The monkeys remained healthy over the next 2 to 3 years. PCR for viral RNA became negative, and virus could no longer be reisolated by coculture. All six macaques were superinfected with the pathogenic SIVmac251/32H. Subsequently, five monkeys became persistently viremic, while one animal was protected against the SIVmac infection. In the peripheral blood mononuclear cells and cocultures of the five viremic animals, DNA from both HIV-2 and SIVmac was present. The plasma contained RNA from both viruses. Thus, superinfection with SIVmac activated HIV-2. A proliferative T-cell response against both HIV-2 and SIVmac was measured in all animals after superinfection. Such a response was regularly seen after infection with the apathogenic HIV-2 but never when the pathogenic SIVmac alone was administered. While naive control monkeys inoculated with SIVmac251/32H regularly develop AIDS-like symptoms soon after infection and have to be killed, none of the preinfected animals has developed AIDS-like symptoms, but two of six animals developed tumors. After the SIVmac challenge, however, apoptotic lymphocytes were detected in the peripheral blood mononuclear cells of all animals. Thus, the presence of an apathogenic viral variant seems to retard the disease occurring after infection with a pathogenic virus rather than to confirm total protection. This partial protection appears to depend on a specific proliferative T-cell response early after infection.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853490      PMCID: PMC188750     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  9 in total

1.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection.

Authors:  M T Kyaw-Tanner; W F Robinson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.

Authors:  E Jurkiewicz; G Hunsmann; J Schäffner; T Nisslein; W Lüke; H Petry
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

5.  Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines.

Authors:  B R Gundlach; S Reiprich; S Sopper; R E Means; U Dittmer; K Mätz-Rensing; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

Review 6.  Efficacy of AIDS vaccine strategies in nonhuman primates.

Authors:  Klaus Uberla
Journal:  Med Microbiol Immunol       Date:  2005-04-21       Impact factor: 3.402

7.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure.

Authors:  Rose Tsui; Belinda L Herring; Jason D Barbour; Robert M Grant; Peter Bacchetti; Alex Kral; Brian R Edlin; Eric L Delwart
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

Review 9.  Restrictions to cross-species transmission of lentiviral infection gleaned from studies of FIV.

Authors:  Sue VandeWoude; Jennifer Troyer; Mary Poss
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.